New Delhi: Revised maximum retail prices (MRPs) for 1,364 anti-cancer medicine formulations have come into effect nationwide, a move projected to save consumers approximately Rs 3,540.38 crore annually. The price adjustments are part of ongoing efforts to enhance the affordability of cancer treatment across the country.
The Chenab Times has learned that the National Pharmaceutical Pricing Authority (NPPA), operating under the Department of Pharmaceuticals and the Union Ministry of Chemicals and Fertilizers, has implemented these revised prices following the capping of trade margins on the MRPs of 137 anti-cancer drugs. This decision was based on recommendations from an Expert Committee established by the Directorate General of Health Services (DGHS) on October 17, 2026.
As of November 8, a total of 85 pharmaceutical firms have reported updated MRPs for 1,364 anti-cancer formulations, encompassing 121 distinct drugs. The price revisions have led to substantial reductions, with 679 brands experiencing a decrease of more than 50 percent in their MRPs. The highest reported price reduction reached an impressive 96.45 percent, underscoring the significant impact of the new pricing policy.
The NPPA has made these revised prices effective to ensure that cancer treatment becomes more accessible to a larger population. The authority has encouraged consumers to verify the revised MRPs printed on medicine packaging. For further assurance, consumers can also utilize the Pharma Sahi Daam mobile application or visit the NPPA website to check the approved prices.
Chemists and hospital pharmacies are now mandated to adhere to the revised MRPs and cannot charge consumers more than the printed price. The Ministry of Chemicals and Fertilizers has emphasized that strict compliance is expected from all retailers and healthcare providers.
To facilitate consumer oversight and address any potential discrepancies, mechanisms for lodging complaints have been put in place. Consumers facing issues related to overcharging or other pricing irregularities can register their grievances through the Pharma Jan Samadhan portal. Additionally, the NPPA provides a dedicated helpline at 1800-111-255 for immediate assistance and reporting of violations.
This initiative is part of a broader strategy by the Indian government to reduce the financial burden associated with critical illnesses like cancer, aiming to improve healthcare outcomes for all citizens. The revised pricing structure is expected to bring relief to thousands of families grappling with the high costs of cancer medication.
The Chenab Times News Desk
